product
Avacta Anti-diUbiquitin K48-linkage Affimer (36-16)
1 April 2015 | By Avacta Life Sciences
Lys-48-linked chains are involved in protein degradation via the proteasome. Affimers are engineered to outperform antibodies and aptamers...
List view / Grid view
Screening
news
Consortium signs deal with Basilea to develop resistance-busting cancer drugs
1 April 2015 | By Victoria White
A consortium will collaborate with Basilea to progress a new family of cancer drugs designed to block several key cancer-causing proteins at once...
product
Avacta Anti-Human SUMO1 Affimer (HS1-A1)
1 April 2015 | By Avacta Life Sciences
A ubiquitin-like protein that can be covalently attached to proteins as a monomer or a lysine-linked polymer...
news
Selvita initiates IND-enabling studies for its first-in-class PIM/FLT3 inhibitor
31 March 2015 | By Victoria White
Selvita announced today that it is commencing IND-enabling studies for SEL24 project, the company’s first oncology drug candidate...
news
Invectys raises 1.7 million euros more to finance the clinical development of its therapeutic cancer vaccine
31 March 2015 | By Victoria White
Invectys has announced fundraising of 1.7 million euros from its original group of private investors, accelerating the clinical development of INVAC-1...
news
Pfizer appoints Dr Charles Reay Mackay as Chief Scientific Officer, Inflammation and Immunology Research Unit
31 March 2015 | By Victoria White
Pfizer Inc. has announced that Charles Reay Mackay will join the company as Chief Scientific Officer for Pfizer’s Inflammation and Immunology Research Unit...
news
CRT and BioInvent expand collaboration with University of Southampton to develop new immunotherapy treatments for cancer
30 March 2015 | By Victoria White
CRT and BioInvent have announced the start of a two-year research collaboration with leading antibody researchers at the University of Southampton...
news
MRC and UCB collaborate to offer access to UCB’s novel antibody discovery platform
30 March 2015 | By Victoria White
The MRC and UCB are to launch a collaboration that will provide scientists with access to cutting-edge technologies to discover new monoclonal antibodies...
news
Cellectis announces pricing of its initial public offering of American Depositary Shares
30 March 2015 | By Victoria White
Cellectis has announced the pricing of its initial public offering of 5,500,000 ADSs at a price to the public of $41.50 per ADS...
news
Taconic Biosciences and Cellaria Biosciences agree to scientific collaboration to facilitate xenograft use in oncology research
26 March 2015 | By Victoria White
Taconic and Cellaria have entered into a scientific collaboration to facilitate use of patient-derived xenografts in animal models for oncology research...
news
AstraZeneca to collaborate with the HSCI in search for new diabetes treatments
25 March 2015 | By Victoria White
AstraZeneca to collaborate with the HSCI to adapt a technique that creates human beta cells from stem cells to search for new treatments for diabetes...
news
Cancer Research UK partners with the Engineering and Physical Sciences Research Council (EPSRC) to inspire innovation
25 March 2015 | By Victoria White
Cancer Research UK has partnered with the EPSRC to co-fund multidisciplinary research projects with up to £37.5m in funding available over five years...
news
Bristol-Myers Squibb acquires exclusive license from Novo Nordisk for a discovery research programme focused on autoimmune diseases
24 March 2015 | By Victoria White
Bristol-Myers Squibb acquires license from Novo Nordisk for a discovery biologics research programme focused on modulating the innate immune system...
article
Meet the editorial board members who influenced the Spring 2015 issue
Editor Caroline Richards talks about the editorial board members who have influenced the content coming up in the latest issue of Drug Target Review, available in April 2015...
news
Confluence Pharmaceuticals signs co-development and marketing agreement with AOP Orphan for Fragile X Syndrome drug
23 March 2015 | By Victoria White
Confluence and AOP have signed an agreement to co-develop and market a product for the treatment of Fragile X Syndrome in Europe and the Middle East...
